Zoetis Feline OA (11/3/2022)

CB Partner Webinar {{webinarsregistrationpage::webinar_title}} {{webinarsregistrationpage::race_approved}} true 1 Credit Hour {{webinarsregistrationpage::hero_image}} {{webinarsregistrationpage::hero_image_self_hosted}} {{webinarsregistrationpage::hero_image_desktop_background_position}} {{webinarsregistrationpage::hero_image_mobile_background_position}} {{webinarsregistrationpage::hero_image_custom_padding}} {{webinarsregistrationpage::hero_image_custom_padding_mobile}} Zoetis {{webinarsregistrationpage::supported_by}} {{webinarsregistrationpage::multiple_speakers}}

Nerve growth factor (NGF) has emerged as an important target to control osteoarthritis (OA) pain. One highly effective way to target NGF is through the use of monoclonal antibodies (mAbs), for which there is now an approved and available option for veterinarians. In this webinar, Dr. Tamara Grubb will describe the role of NGF in the pain pathway and share her experience in using the first and only feline anti-NGF mAb therapy. Challenges in identifying and treating chronic pain in cats will also be discussed.

{{webinarsregistrationpage::inside_the_webinar_2}} {{webinarsregistrationpage::inside_the_webinar_3}} How to identify OA pain in cats Appreciate why and how untreated pain is highly detrimental to our patients Recognize the role of NGF in the development of chronic, maladaptive pain Understand how an anti-NGF mAb can control OA pain in cats {{webinarsregistrationpage::what_youll_learn_bullet_5}} {{webinarsregistrationpage::what_youll_learn_bullet_6}} {{webinarsregistrationpage::additional_subhead}} {{webinarsregistrationpage::additional_copy}} In adherence with RACE guidelines, CE certificates can only be distributed to individual registrants under the name used upon registration. Group viewers will not be eligible to receive multiple CE certificates.